A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT)

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

July 2, 2025

Study Completion Date

December 31, 2025

Conditions

Chemotherapy-induced Thrombocytopenia (CIT)

Interventions

BIOLOGICAL

Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein

Recombinant Human Tumor Necrosis Factor Receptor II -Fc-TPO Mimetic Peptide Fusion Protein for injection (Strength: 1 mg/ml, 0.5ml/vial)

Trial Locations (1)

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Sichuan Clover Biopharmaceuticals, Inc.

INDUSTRY

NCT05426369 - A Clinical Trial Evaluating SCB-219M in in Chemotherapy-induced Thrombocytopenia (CIT) | Biotech Hunter | Biotech Hunter